Zydus Lifesciences rises on getting final nod to manufacture, market Sucralfate Tablets
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Zydus Lifesciences is currently trading at Rs. 523.50, up by 3.60 points or 0.69 % from its previous closing of Rs. 519.90 on the BSE.
The scrip opened at Rs. 523.50 and has touched a high and low of Rs. 523.50 and Rs. 523.50 respectively. So far 236 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 527.95 on 02-May-2023 and a 52 week low of Rs. 319.40 on 11-May-2022.
Last one week high and low of the scrip stood at Rs. 527.95 and Rs. 504.45 respectively. The current market cap of the company is Rs. 52624.49 crore.
The promoters holding in the company stood at 74.98%, while Institutions and Non-Institutions held 17.02% and 8.00% respectively.
Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Sucralfate Tablets USP, 1 gram (USRLD: Carafate Tablets, 1 gram). Sucralfate is used to treat and prevent ulcers in the intestines by forming a coating over ulcers, protecting the area from further injury. This helps ulcers heal more quickly. The drug will be manufactured at the group’s topical manufacturing facility at SEZ, Ahmedabad (India).
Sucralfate Tablets USP, 1 gram had annual sales of $84 million in the United States (IQVIA MAT February 2023). The group now has 367 approvals and has so far filed over 440 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.
